Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endocrine therapy effects on postoperative lipid metabolism in postmenopausal breast cancer
ChiCTR-OCS-13004203Phase 4Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anastrozole, letrozole, exemestane and tamoxifen in breast cancer (4 cohorts), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Triglycerides. Started Oct 2013; status: completed.
02
Drugs
anastrozoleletrozoleexemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OCS-13004203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCS-13004203.